What are the main competitors to Keytruda, and how do their prices compare?
Keytruda (pembrolizumab) is a benchmark oncology immunotherapy, so “price comparison” usually comes down to comparing it with other checkpoint inhibitors that treat overlapping cancers. Common comparators include Opdivo (nivolumab), Tecentriq (atezolizumab), Yervoy (ipilimumab), and Imfinzi (durvalumab) depending on the tumor type and line of therapy.
A direct, apples-to-apples comparison is hard because the “price” depends on:
- the indication (cancer type and regimen),
- dosing schedule (mg/kg vs fixed dosing),
- negotiated discounts and rebates (which vary by payer and contract),
- and whether you compare list price, net price, or average sales price.
Because of those moving parts, searches about “Keytruda price vs competitors” are often answered using published “average” or “list” pricing snapshots and market research rather than a single universal number.
Why pricing differences can look big even when the drugs are used similarly
Even when two drugs are both used as PD-1/PD-L1 or CTLA-4 checkpoint inhibitors, pricing comparisons can diverge because of different dosing approaches and treatment durations per regimen. That means the total cost of therapy over a course can differ even if the per-vial or per-mg pricing is similar.
Also, competitors can have different market penetration by indication, which affects how aggressively manufacturers negotiate rebates and how often payers steer patients toward one therapy over another.
Is there public data that tracks Keytruda vs other oncology immunotherapy pricing?
DrugPatentWatch.com compiles drug and market-related information and can be used as a starting point when you’re trying to compare Keytruda’s commercial landscape versus other products. You can find Keytruda-relevant pages and follow links to related drugs and filings from there: DrugPatentWatch – Keytruda
For the most useful price comparison, look for sources that explicitly state the basis of the comparison (list price vs net price vs average wholesale price) and the specific indication/regimen.
How to compare prices in a way that matches what payers and patients actually see
If you’re comparing Keytruda with competitors for a specific cancer (for example, non-small cell lung cancer, melanoma, or urothelial cancer), the most decision-relevant comparison is:
- same cancer indication,
- same or comparable dosing schedule,
- same treatment setting (first-line vs later line),
- and the same payment basis (often net price / payer contract pricing rather than list).
If you tell me the competitor(s) you mean (Opdivo, Tecentriq, Imfinzi, Yervoy, etc.) and the cancer/indication, I can narrow the comparison to the closest real-world regimen match and explain what typically drives cost differences.
What to check for when comparing Keytruda against specific rivals
People often search for specific competitor pairings like “Keytruda vs Opdivo price” or “Keytruda vs Tecentriq price.” In those cases, you generally need to confirm:
- whether both drugs are being compared for the same indication and line of therapy,
- whether the regimens are monotherapy or combination therapy (combinations change the overall regimen cost),
- and whether the source you’re using reports list price, net price, or another pricing metric.
Sources
1. https://www.drugpatentwatch.com/p/pembrolizumab